Skip to main content

Compare Stocks

Date Range: 

 Pharvaris B.V.iTeos TherapeuticsFinch Therapeutics GroupGracell BiotechnologiesPharming Group
SymbolNASDAQ:PHVSNASDAQ:ITOSNASDAQ:FNCHNASDAQ:GRCLNASDAQ:PHAR
Price Information
Current Price$21.36$24.48$12.04$11.05$12.11
52 Week RangeBuyBuyBuyBuyN/A
MarketRank™
Overall Score1.51.92.01.40.0
Analysis Score3.43.53.53.50.0
Community Score3.93.75.03.30.0
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.70.00.0
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$47.50$47.33$29.33$34.50N/A
% Upside from Price Target122.38% upside93.36% upside143.63% upside212.22% upsideN/A
Trade Information
Market Cap$680.10 million$859.27 million$567.63 million$742.70 million$776.60 million
BetaN/AN/AN/AN/AN/A
Average Volume87,988260,110144,444124,8287,176
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E Ratio∞N/A∞∞201.83
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/A71.07%N/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A62131202262
Shares Outstanding31.84 million35.10 million47.15 million67.21 million64.13 million
Next Earnings Date7/29/2021 (Estimated)8/12/2021 (Estimated)N/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Pharming Group NV (PHAR)Pharming Group NV (PHAR)
investing.com - May 15 at 12:26 AM
Pharming Group (NASDAQ:PHAR) Shares Gap Down to $13.00Pharming Group (NASDAQ:PHAR) Shares Gap Down to $13.00
americanbankingnews.com - May 14 at 12:12 PM
Hereditary Angioedema Market Size 2021 Research Report by Business Distribution, Shipments, Price, Revenue, Gross Profit and Forecast to 2025Hereditary Angioedema Market Size 2021 Research Report by Business Distribution, Shipments, Price, Revenue, Gross Profit and Forecast to 2025
marketwatch.com - May 13 at 2:11 PM
Pharming Group (NASDAQ:PHAR) Hits New 12-Month Low at $12.00Pharming Group (NASDAQ:PHAR) Hits New 12-Month Low at $12.00
americanbankingnews.com - May 13 at 1:40 PM
Heres what Wall Street expects from Pharming Group NVs earnings reportHere's what Wall Street expects from Pharming Group NV's earnings report
markets.businessinsider.com - May 13 at 9:10 AM
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumePharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume
americanbankingnews.com - May 10 at 3:26 PM
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreasePharming Group (NASDAQ:PHAR) Sees Large Volume Increase
americanbankingnews.com - May 3 at 12:04 PM
Short Interest in Pharming Group (NASDAQ:PHAR) Drops By 92.2%Short Interest in Pharming Group (NASDAQ:PHAR) Drops By 92.2%
americanbankingnews.com - April 28 at 6:36 AM
Trusted Notifiers and the Future of DNS AbuseTrusted Notifiers and the Future of DNS Abuse
circleid.com - April 27 at 1:45 PM
Pharming Group (NASDAQ:PHAR) Stock Price Down 4.7%Pharming Group (NASDAQ:PHAR) Stock Price Down 4.7%
americanbankingnews.com - April 26 at 12:48 PM
Analyzing The Price Action In SVB Finl Gr Stock TodayAnalyzing The Price Action In SVB Finl Gr Stock Today
benzinga.com - April 25 at 8:21 AM
Pharming Group (NASDAQ:PHAR) Shares Gap Down to $13.55Pharming Group (NASDAQ:PHAR) Shares Gap Down to $13.55
americanbankingnews.com - April 23 at 11:16 AM
Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarctionPharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
finance.yahoo.com - April 22 at 9:34 AM
Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange CommissionPharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
finance.yahoo.com - April 7 at 6:47 PM
DNS ABUSE FORUMDNS ABUSE FORUM
circleid.com - March 18 at 9:43 AM
The Knights Orchestra Announces Leadership ChangeThe Knights Orchestra Announces Leadership Change
broadwayworld.com - March 4 at 5:52 PM
Heres what Wall Street expects from Pharming Group NV American Depositary Shares Repr 10s earningsHere's what Wall Street expects from Pharming Group NV American Depositary Shares Repr 10's earnings
markets.businessinsider.com - March 2 at 12:40 PM
Pharming Group NV earnings: heres what Wall Street expectsPharming Group NV earnings: here's what Wall Street expects
markets.businessinsider.com - March 2 at 12:40 PM
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program navigateAPDS in US and CanadaPharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada
finance.yahoo.com - March 2 at 2:39 AM
PIR Launches New Institute to Combat DNS AbusePIR Launches New Institute to Combat DNS Abuse
wfmz.com - February 17 at 4:42 PM
Org behind .org launches DNS Abuse InstituteOrg behind .org launches DNS Abuse Institute
scmagazine.com - February 17 at 11:42 AM
DateCompanyBrokerageAction
4/25/2021Pharvaris B.V.SVB LeerinkInitiated Coverage
3/8/2021Pharvaris B.V.Morgan StanleyReiterated Rating
3/8/2021Pharvaris B.V.OppenheimerInitiated Coverage
3/8/2021Pharvaris B.V.Bank of AmericaInitiated Coverage
5/11/2021iTeos TherapeuticsHC WainwrightInitiated Coverage
3/25/2021iTeos TherapeuticsWedbushBoost Price Target
10/7/2020iTeos TherapeuticsRobert W. BairdInitiated Coverage
8/18/2020iTeos TherapeuticsJPMorgan Chase & Co.Initiated Coverage
8/18/2020iTeos TherapeuticsPiper SandlerInitiated Coverage
4/19/2021Finch Therapeutics GroupJefferies Financial GroupInitiated Coverage
4/19/2021Finch Therapeutics GroupEvercore ISIInitiated Coverage
2/3/2021Gracell BiotechnologiesCitigroupInitiated Coverage
2/2/2021Gracell BiotechnologiesWells Fargo & CompanyInitiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.